Orthofix Medical Inc. (OFIX) AI Stock Analysis

Orthofix Medical Inc. is a medical device and biologics company operating in the United States, Europe, Brazil, and internationally. The company operates through two segments: Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for bone fusion, motion preservation and fixation implant products for spine surgeries, and regenerative non-tissue biologic solutions. The Global Orthopedics segment designs, develops, and markets orthopedic products for fracture repair, deformity correction, and bone reconstruction. Orthofix distributes its products through direct sales representatives and independent distributors to physicians, hospitals, ambulatory surgery centers, and healthcare purchasing organizations.

Orthofix increased revenue from $464.5M in FY2021 to $822.3M in FY2025, recording a 5-year revenue CAGR of 15.1% from FY2020 to FY2025. Annual revenue expanded 62.1% in FY2023 to $746.6M, followed by growth of 7.1% in FY2024 and 2.9% in FY2025. However, profitability remained negative, with net losses of -$151.4M in FY2023, -$126.0M in FY2024, and -$92.2M in FY2025. Gross margin contracted from 75.3% in FY2021 to 67.1% in FY2025, while operating margin moved from -1.8% to -8.3%. For the latest quarter ended June 30, 2026, quarterly revenue growth was 3.8% year-over-year, bringing trailing twelve-month revenue to $833.2M with diluted EPS of -$1.52.

As of June 30, 2026, Orthofix held $103.8M in cash and short-term investments against total debt of $234.6M, resulting in net debt of $130.8M. Total assets stood at $873.0M and shareholders' equity was $429.2M, with a debt-to-equity ratio of 0.55 and a current ratio of 2.84. In FY2025, operating cash flow reached $33.3M while capital expenditures were $34.6M, resulting in free cash flow of -$1.3M. Over the past five years, the company's share count increased by 106.0%.

At a closing price of $9.38 on October 16, 2026, Orthofix had a market capitalization of $379.2M and an enterprise value of $504.7M. The stock trades at a price-to-sales multiple of 0.5x and an EV-to-EBITDA ratio of 26.6x, compared to the median of its US-listed Healthcare peers of 4.1x and 12.0x, respectively. Its forward P/E stands at 500.0x versus the peer median of 17.3x, alongside a price-to-book ratio of 0.9x. Over the past year, Orthofix returned -38.5%, trailing the S&P 500 return of 16.8%.

Wall Street analysts cover Orthofix with 2 Strong Buy, 1 Buy, and 2 Hold ratings, with no Sell or Strong Sell ratings. The mean price target of $13.00 implies an upside of 38.6% from the last close of $9.38. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $851.2M and EPS of $0.41, representing an EPS decline of 15.9%. The company beat EPS estimates in each of the last 4 quarters, and its next earnings date is November 3, 2026.

This page is an AI-written research summary of Orthofix Medical Inc. (OFIX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: OFIX income statement, OFIX balance sheet, OFIX key metrics, OFIX analyst forecast, OFIX chart. See the OFIX stock overview for the latest quote and news.